Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

NCT00847613 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00847613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00847613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
February 29, 2012
Enrollment
800 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid